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Edited by I. B. HollandAbstractThe eukaryotic actin cytoskeleton is an evolutionarily well-established pathogen target, as a large number of
bacterial factors disturb its dynamics to alter the function of the host cells. These pathogenic factors modulate
or mimic actin effector proteins or they modify actin directly, leading to an imbalance of the precisely regulated
actin turnover. Here, we show that the pore-forming, cholesterol-dependent cytolysin pneumolysin (PLY), a
major neurotoxin of Streptococcus pneumoniae, has the capacity to bind actin directly and to enhance actin
polymerisation in vitro. In cells, the toxin co-localised with F-actin shortly after exposure, and this direct
interaction was verified by Förster resonance energy transfer. PLY was capable of exerting its effect on actin
through the lipid bilayer of giant unilamellar vesicles, but only when its pore competence was preserved. The
dissociation constant of G-actin binding to PLY in a biochemical environment was 170–190 nM, which is
indicative of a high-affinity interaction, comparable to the affinity of other intracellular actin-binding factors. Our
results demonstrate the first example of a direct interaction of a pore-forming toxin with cytoskeletal
components, suggesting that the cross talk between pore-forming cytolysins and cells is more complex than
previously thought.
© 2012 Elsevier Ltd. Open access under CC BY license.Introduction
Bacteria produce effector molecules, such as
protein toxins, to modulate host cell function and
host defence, thereby increasing bacterial pathogenic
potential. Many bacterial effector molecules are pore-
forming proteins, which build holes in membranes,
thereby damaging cells. The cholesterol-dependent
cytolysin (CDC) pneumolysin (PLY), amajor virulence
factor of Streptococcus pneumoniae (pneumococ-
cus), produces lytic membrane pores at high concen-
trations and smaller, presumably non-lytic, pores at
lower concentrations.1 The formation of pores in-
volves a cholesterol-binding step, in which the toxin0022-2836 © 2012 Elsevier Ltd. Open access under CC BY license.molecules oligomerise into a barrel structure of 30–50
monomers (Fig. 1a). The cholesterol-binding step is
followed by a penetration step, in which components
of the oligomerised toxin molecules unfold and
penetrate the membrane to form the pore.2 PLY
comprises four domains. Domain 4 recognises and
binds to cholesterol in the membrane, while domains
1, 2 and 3 remain external to themembrane in an initial
pre-pore ring structure (schematically depicted in
Fig. 1a). Upon oligomerisation in a pre-pore ring, a
complex conformational change occurs.2,3 Domain 2
bends towards the membrane, allowing the subse-
quent partial refolding of domain 3. In this process, the
helical regions of domain 3, hidden inside theJ. Mol. Biol. (2013) 425, 636–646
Fig. 1. (a) Schematic represen-
tation of the pre-pore and pore
formation by PLY and of the orien-
tation of individual domains (1, 2, 3
and 4) in this process (according to
Tilley et al.2). (b) Schematic repre-
sentation of the non-pore-forming
Δ6-PLY mutant.
637Actin–Cytolysin Pneumolysin Interactionmolecule, are refolded into two β-hairpins (each
containing two parallel β-strands), which penetrate
the membrane and build the internal β-barrel of the
pore2 (schematically depicted in Fig. 1a). For exper-
imental and immunisation purposes, a non-pore-
forming mutant (Δ6-PLY)4 and the fragments D4-
PLY (containing domain 4) andD123-PLY (containing
domains 1, 2 and 3) have been created. Δ6-PLY has
been shown to preserve membrane-binding activity,5
but it lacks the amino acids alanine 146 and arginine
147 at the transition interface fromdomain 1 to domain
3 (Fig. 1b), rendering the toxin non-lytic due to a
compromised refolding and penetration capacity of
domain 3 (Fig. 1b).
In the pore conformation, PLY penetrates the
membrane and can either lyse the cells immediately
or produce ion fluxes and cell shape remodelling.1,5,6
The exact factors determining which cells survive
and which cells are lysed remain elusive. It is
known that cells possess membrane repair mech-
anisms, such as the internalisation of damaged
membrane fragments and pores and replacement
with new intact membranes, which most likely
contribute to the resistance against the effect of
lytic PLY molecules.7,8Our earlier finding of actin cytoskeletal modulation
via the activation of smallGTPases byPLY identified a
surprising function of a CDC,9 but one that is typical of
many other bacterial effectors. PLY is the only known
pore-forming toxin that alters the actin cytoskeleton
via small GTPases in intact cells. The activation of the
small GTPases RhoA and Rac1 by PLY is a complex
phenomenon that involves protein kinase C and
membrane depolarisation and that requires intact
pore-forming capacity.9 In cell culture conditions,
shape changes and actin remodelling are observed
even when using low concentrations of PLY that lyse
less than 5% of all cells (we have defined these
concentrations as sub-lytic). TheΔ6 non-pore-forming
toxin mutants do not affect cell shape or the actin
cytoskeleton, suggesting a role of pore formation
capacity in the shape alterations in surviving cells.5
The eukaryotic actin cytoskeleton is an evolution-
arily well-established pathogen target, as a large
number of bacterial effector proteins alter it. Some
toxins, such as the binary and large clostridial
glucosylating toxins, the Tc toxins of Photorhabdus
luminescens and the actin cross-linking toxins, affect
actin directly.10 Other toxins change the function of
actin-regulating small GTPases by modifying them
Fig. 2. Actin and PLY co-locali-
sation and interaction in astrocytes.
(a) Co-localisation between F-actin
[stained with phalloidin (green)] and
PLY [Atto488-tagged, 0.2 μg/ml
(blue–magenta)] in astrocytes 90 s
after toxin exposure (a single con-
focal plane along the surface of the
cell). The co-localisation highlighter
plugin from ImageJ is applied with
standard settings (ratio, 50%; chan-
nel threshold, 50). The scale bar
represents 10 μm. (b) Principle of
FRET measurements via acceptor
photobleaching. In the case of
FRET (at the molecular interaction
distance between the donor and the
acceptor), the donor fluorescence is
quenched by the acceptor. Upon
bleaching of the acceptor, the donor
is de-quenched, and its fluores-
cence increases. PLY is labelled
with Atto488 (PLY-Atto488; donor),
and F-actin is labelled with phalloi-
din-Alexa555 (acceptor). (c) Phal-
loidin staining of cortical F-actin in
an astrocyte monolayer, showing
the border region fragments of four
cells tightly attached to each other.
The ratio of donor fluorescence
before/after bleaching of the accep-
tor demonstrates the presence of
strong FRET along the phalloidin-
positive subcortical F-actin struc-
tures 120 s after the PLY-Atto488
challenge. The scale bar represents
10 μm. (d) Representative profile
scan along the cortical actin struc-
tures shown in (c) demonstrating
the changes in donor fluorescence
after bleaching.
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factors.11 Some toxins have adapted to interact with
actin-binding proteins, such as the Arp2/3 complex
and its regulators.12
The aim of the current work was to study the
possibility of a direct interaction between actin and
PLY in the first minutes after toxin exposure.Results
PLY and actin co-localise transiently at the
plasma membrane shortly after toxin challenge
We used primary mouse astrocytes as amodel cell
system because astrocytes represent the natural
environment of pneumococcal meningitis, where
PLY plays a key role.13 Similar to our earlier report
of small GTPase activation by PLY in human
neuroblastoma cells,9 PLY also activated RhoA
and Rac in astrocytes by 4 min after the toxin
challenge (not shown). Therefore, we followed the
distribution of fluorescent Atto488-labelled PLY and
actin in the first 4 min (Fig. 2a). Ninety seconds after
toxin application, more than the half of all PLY-
Atto488 puncta co-localised with the actin bundles
positioned directly beneath the plasma membrane of
the cells (Fig. 2a, single confocal plane). Confocal z-
stack reconstruction revealed that the toxin puncta
were positioned close to the surface of the cells. To
study whether this co-localisation represented a
direct interaction, we utilised a Förster resonance
energy transfer (FRET) approach, namely, acceptor
photobleaching (Fig. 2b), which was able to show the
interaction of both molecules. F-actin was labelled
with phalloidin-Alexa555 (as the acceptor) in fixed
cells exposed to PLY-Atto488 (as the donor) before
fixation (Fig. 2b). In the first 60 s of PLY-Atto488
exposure, no FRET was observed after acceptor
photobleaching (not shown). In the 90–240 s after
toxin exposure, FRET was observed in three of five
cells following acceptor photobleaching, specifically
along the cortical actin structures (Fig. 2c and d),
which was indicative of the proximity between PLY
and phalloidin-labelled actin being in the range of the
molecular interaction distance (b10 nm). At later timeFig. 3. Biochemical characterisation of PLY binding to actin.
(measured by the dissociation constant Kd) in various stoic
measurements per ratio. (b) Lack of phalloidin binding to PLY, as
measurements (for a rough orientation of the intensity scale, the i
and a volume of 50 μl exceeded 60,000 A.U.). (c) A representa
demonstrating the co-sedimentation of F-actinwithwild-typePLY
mutant. (d) Schematic presentation of the fragments D123 and
according to the toxin domains they comprise. (e) Analysis of G
actin concentration is 2.2 μM, corresponding to the plateau of the
to the domain 1–3 fragment of PLY (D123-PLY) and not to the
intermediate binding. ⁎⁎pb0.01, ⁎⁎⁎pb0.001, n=6. All the valuespoints (N240 s), FRET was no longer detected (not
shown); however, PLY was observed internalised in
vesicular structures (Supplementary Fig. S1), and no
substantial co-localisation with actin was observed.
Thus, a direct interaction between PLY and actin was
observedwithin the first 4 min after treatment with the
toxin, and this interaction was of a transient (i.e., the
interaction only lasted several minutes) nature.
PLY binds actin with high affinity
Biochemical quantification of the affinity of the
interaction between PLY and actin allows for a
comparison with other known actin-binding factors.
A suitable marker for the affinity of this interaction is
the dissociation constant Kd. Lower Kd values
correspond to higher-affinity interactions. We devel-
oped an ELISA-based assay in which PLY-coated
surfaces were exposed to varying concentrations of
G-actin or fluorescently labelled phalloidin (Fig. 3a
and b). G-actin bound PLY with a high affinity,
demonstrating a Kd of 170–190 nM (Fig. 3a); phalloi-
din did not bind PLY (Fig. 3b). These results verified
that the FRET experiments detected an interaction
between PLY and actin and not with phalloidin. To
verify that the Kd for the affinity of actin binding to PLY
was not falsely derived due to stoichiometric satura-
tion (i.e., when no more binding positions on PLY
molecules were available due to the binding of
excessive amounts of actin), we repeated the
experiment at several different stoichiometric ratios
(changing the amount of coated PLY) and obtained
identical results (Fig. 3a; for the exact protocol details,
see Materials and Methods). PLY also bound pre-
formed F-actin filaments and co-sedimented with
them after ultracentrifugation (Fig. 3c). The co-
sedimentation of the non-pore-forming toxin mutant
Δ6-PLYwith actin filamentswas substantially reduced
compared to the co-sedimentation observedwithwild-
type PLY (Figs. 3c and 1b and Introduction).4
The domains of PLY critical for pore formation
are also essential for the interaction of PLY
with actin
We analysed individual fragments of PLY to
determine which domains are mechanistically(a) ELISA-based measurement of the G-actin affinity to PLY
hiometric ratios, which produce identical results. n=3–5
measured by the fluorescence of phalloidin-Alexa488. n=4
ntensity of the initially applied phalloidin-Alexa488 at 260 μM
tive experiment (performed in triplicate with identical results)
(WT-PLY) and the reducedco-sedimentation of thePLYΔ6-
D4, which were utilised in the binding ELISA assay in (e),
-actin binding to different forms and fragments of PLY. The
affinity curve in (a). G-acting binds strongest toWT-PLYand
domain 4 fragment (D4-PLY). The Δ6-PLY mutant shows
represent the mean±SEM.
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641Actin–Cytolysin Pneumolysin Interactionnecessary for actin binding. We expanded the ELISA
interaction assay to include the Δ6-PLY mutant and
PLY fragments. We used two fragments of PLY: one
containing domain 4 only (domain 4 binds cholesterol
in the membrane but does not penetrate it; see Figs.
1a and 3d) and another fragment comprising
domains 1, 2 and 3, which are critically important
for the ability of the toxin to penetrate the membrane
(see Figs. 1 and 3d). The strongest binding was
demonstrated by the fragment containing domains 1,
2 and 3, compared to the domain 4 fragment (Fig. 3e).
The Δ6-PLY mutant bound actin more weakly than
wild-typePLY but bound actin stronger than themock
control (Fig. 3e). These experiments indicated that
the toxin domains and amino acids that are involved
in and are critical for PLY pore formation are also
important for interaction of the PLY with actin.
PLY enhances actin polymerisation
Next, we addressed whether PLY binding to actin
can also alter actin dynamics, namely, actin poly-
merisation and depolymerisation. We analysed the
F-actin/G-actin ratio following the polymerisation of
actin in actin polymerisation buffer (APB) in the
absence and presence of PLY. PLY enhanced the
polymerisation of the monomeric G-actin into F-actin
(Fig. 4a). A similar effect was observed when
fluorescence recovery after photobleaching (FRAP)
was performed on rhodamine-labelled actin in APB.
The FRAP approach is a powerful tool for studying
the level of polymerisation of fluorescent molecules,
as the molecular diffusion (measured by the half-
time of fluorescence recovery) decreases as the size
of the oligomers increases. The formation of large
non-diffusing fluorescent polymers is detected as an
immobile fraction (i.e., the portion that does notby FRAP analysis of actin-rhodamine 60 min after exposure to
the actin-rhodamine in solution (for 5 s at maximum 561 nm las
followed in the bleached area. The longer half-time of fluores
fragments. The larger immobile fraction indicates a larger, c
fraction. n=4 experiments. All the values represent the meandiffuse and does not recover fluorescence after
bleaching14). The longer half-time of recovery of
fluorescent actin in the presence of PLY and the
increased immobile fraction indicated stronger actin
oligomerisation and polymerisation, respectively,
compared to actin in the presence of IgG (as a
control protein) (Fig. 4b). This result confirmed that
PLY not only binds actin but can also interfere with
its polymerisation status.
PLY interacts with actin through lipid bilayers
Affinity measurement experiments and the analysis
of actin polymerisation were performed under condi-
tions in which no lipid bilayer separated PLY from its
interacting partners. However, such a membrane
barrier does exist in cells. To test whether PLY and
actin can interact directly through amembrane bilayer
devoid of additional traffic/repair properties, we
utilised a giant unilamellar vesicle (GUV) approach.15
In this system, giant (5–30 μm indiameter)membrane
bilayer vesicles were prepared by electroformation.16
The components of the system were limited to
phospholipids and cholesterol in the membrane,
rhodamine-labelled actin and the Arp2/3 protein
complex outside of the GUVs and PLY-green
fluorescent protein (GFP) within the GUVs. The
loading of PLY-GFP inside the GUVs was achieved
using a liposome carrier (see Materials and Methods)
via 4 °C fusion16 (Fig. 5a). With this approach, we
reproduced the orientation of PLY and actin on both
sides of the bilayer. No freePLYorPLY that bound the
GUVs on the external surface was present in the
system (see Materials and Methods and Supplemen-
tary Fig. S2). Actin was incubated in APB to provide
the ATP and Mg2+ necessary for polymerisation,
which, together with Arp2/3, allowed for slow butFig. 4. Increased actin polymer-
isation in the presence of PLY. (a)
Increased actin stabilisation (in-
creased F-actin in the protein pellet
versus G-actin in the solution after
sedimentation of F-actin by ultra-
centrifugation at 150,000g for
90 min) in the presence of 600 nM
PLY for 1 h at 24 °C. The amount of
actin was measured by anti-actin
Western blot analysis. ⁎pN0.05, n=
5 experiments. (b) Increased actin
polymerisation caused by PLY, but
not by IgG (control protein), in a
biochemical system, as determined
the APB (which provides Mg2+ and ATP). After bleaching of
er power), the change in fluorescence due to diffusion was
cence recovery indicates larger and more slowly diffusing
ompletely immobile and presumably highly polymerised
±SEM.
642 Actin–Cytolysin Pneumolysin Interactiondetectable spontaneous polymerisation. This poly-
merisation was visible as small actin clusters on the
surface of the GUVs after 30–60 min. Thus, this
system allows for the analysis of both actin stabilisa-
tion and actin destabilisation, depending on how and ifFig. 5. Transmembrane actin clustering by PLY in GUVs
approach for the fusion of liposomes (for a complete descript
molecules are positioned on opposite sides of the lipid bilayer
GUVs in close proximity to the PLY-GFP clusters is observed
sample or with the non-pore-forming Δ6-PLY GUVs. The scale
intensity distribution along the GUV surface normalised to the a
(measured at a distance of one diameter from the surface of the
15 to 20 GUVs in one representative experiment (the mean onl
results. (d) Increased actin aggregation (as measured by the
background) in the WT-PLY GUVs. ⁎pb0.05; the values
representative experiment.the PLY-GFP has an effect. We observed that wild-
type PLY-GFP accelerated the aggregation and
polymerisation of actin-rhodamine on the GUV sur-
face (Fig. 5b–d), as PLY-GFP puncta co-localised
with the largest actin-rhodamine clusters (Fig. 5b,. (a) Schematic representation of the GUV experimental
ion, see Materials and Methods). The toxin and the actin
. (b) Aggregation of actin-rhodamine on the surface of the
with wild-type PLY (WT-PLY; arrows), but not in the mock
bar represents 10 μm. (c) Cumulative histogram of the pixel
verage actin-rhodamine staining intensity outside the GUV
GUV). The histogram represents the cumulative data from
y). The experiment was repeated three times with identical
increased rhodamine staining intensity above the actin
represent the mean±SEM of 15–20 GUVs within one
643Actin–Cytolysin Pneumolysin Interactionarrows). The non-pore-forming Δ6-GFP mutant,
which also partially clustered in the membrane
(fluorescent puncta in Fig. 5b), did not produce the
same effects on actin-rhodamine as the wild-type
PLY-GFP did. TheseGUV experiments confirmed the
ability of PLY to target actin through the lipid bilayer,
but only when the toxin can form pores.Discussion
The aim of the current work was to obtain
mechanistic insights into the earliest effects of PLY
on cellular actin. The results revealed selective and
high-affinity (Kd of 170–190 nM) binding of PLY to
actin and the ability of PLY to enhance actin
polymerisation in vitro. The effects of PLY were
dependent on its pore formation capacity, suggest-
ing that the active actin-interacting partner is the
toxin in a pore state. The interaction was transient,
occurring shortly after PLY binding to the membrane
and ceasing with the internalisation of the toxin. The
actin interaction described here represents the first
evidence for a direct interaction between a pore-
forming toxin and actin. These results complement
our previous findings of small GTPase-dependent
cellular modifications by PLY that occur after longer
(N4 min)9 exposure to the toxin. Whether actin
polymerisation is mechanistically related to the
later activation of small GTPase has to be addressed
in further studies. Evidence from cardiomyocytes
indicates that the actin changes produced by cell
stretching can secondarily activate RhoA and Rac1
small GTPases.17 Thus, it is possible that the small
GTPase effects of PLY occur secondary to its actin
rearrangement effects.
The interaction between actin and PLY is relatively
strong (Kd of 170–190 nM) and is comparable to the
binding affinity of phalloidin to F-actin (116 nM18)
and of the Arp2/3 complex to F-actin (ATP bound,
40 nM; ADP bound, 1 μM19). After binding the
membrane, the molecules of PLY distribute linearly
in the monolayer of the membrane, as the linear
concentration can reach very high values. The actin
concentration directly beneath the membrane is also
very high.20 Thus, the interface between the
membrane and cytosol is molecularly favourable
for a direct interaction between actin and PLY.
Consistent with the current knowledge about pore
formation, a critical role in actin binding was
observed for the membrane-penetrating portion of
domain 3. The domain-3-containing fragment was
the strongest actin-binding partner in the ELISA
assays, and the deletion of alanine 146 and arginine
147 (the Δ6 mutation present in domain 3 blocks the
toxin transition from a pre-pore to a pore and,
therefore, the penetration through the membrane)
in the full-length PLY molecule decreased its ability
to bind and cluster actin at the GUV membrane. Thedecreased actin binding to the Δ6 mutant in the
ELISA assay where no membrane was present,
however, suggested that alanine 146/arginine 147
are also important for actin binding, irrespective of
the presence of a membrane. Considering that these
amino acids remain relatively high above the level of
the membrane during pore formation,2 it is likely that
they facilitate the refolding of domain 3 rather than
directly interacting with actin. The membrane-pene-
trating β-strand hairpins (of domain 3) that build the
β-barrel of the pore are most likely the effective actin-
binding interfaces.
PLY is a critical pathogenic factor, aggravating the
course of pneumococcal infections.21,22 It is difficult
to judge the contribution to the progress of S.
pneumoniae infection of either the actin-binding
and stabilisation effects of PLY or its small GTPase
activation in an isolated manner because these are
always present with the formation of the pore by the
toxin. However, even short-term modulation of actin
turnover by PLY might affect the properties of actin-
dependent structures of the organism (such as the
blood–brain barrier and liver) and thus facilitate the
propagation of S. pneumoniae. Indeed, knocking out
PLY or neutralising the toxin by antibodies dimin-
ishes the invasive potential of pneumococci in model
animals, prevents bacteraemia and inhibits the
colonisation of various organs.23,24
In recent work,25 Vadia et al. describe the
increased internalisation of beads and bacteria
coated with the CDCs listeriolysin or PLY. The
transmembrane actin binding by PLY that we
observed could therefore contribute to the alterations
in cell trafficking and the toxin-induced internalisation
of particles. The internalisation of pneumococci is
known to be important for the pathogenesis of the
disease (e.g., for penetration through the blood–brain
barrier).26 It is also possible that the interaction
between PLY and actin initiates the endocytotic
internalisation of the toxin, which interrupts actin
binding and thus determines its transient nature. In
cells, the interactions between actin and the actin-
associated proteins are complex. PLY may also bind
some of these complexes together with actin. Upon
pore formation and subsequent calcium influx,27 the
cleavage of some of these interaction partners (e.g.,
talin and/or vinculin) in a calcium-dependent manner
(e.g., by calpain)28 could be another reason for the
interruption of the PLY/actin interaction.
In conclusion, we demonstrate that PLY has the
capacity to penetrate membranes in both cells and
model bilayers in a manner that enables the toxin to
interact with sub-membranous actin with a high
affinity, which induces actin polymerisation. This
interaction involves motifs in domains 1–3 of the
toxin, which are also required for the pore-forming
ability of PLY.5 Thus, PLY emerges as the first
example of a pore-formingbacterial toxin that interacts
directly with actin, which, together with its capacity to
644 Actin–Cytolysin Pneumolysin Interactionactivate small GTPases, completes its profile as a
specific actin cytoskeleton-remodelling factor.Materials and Methods
PLY preparation
Wild-type PLY and N-terminally GFP-tagged PLY (PLY-
GFP) were expressed in Escherichia coli BL-21 cells
(Stratagene, Cambridge, UK) and purified by metal affinity
chromatography as described previously.29 The purified
PLY was evaluated for the presence of contaminating
Gram-negative lipopolysaccharide using the colorimetric
Limulus amebocyte lysate assay (KQCL-BioWhittaker,
Lonza, Basel, Switzerland). All purified proteins showed
b0.6 endotoxin units per microgram of protein. The initial
stock of purified wild-type toxin exhibited an activity of
approximately 5×104 haemolytic units per milligram. The
non-toxic Δ6 form of the toxin was constructed by site-
directed mutagenesis (QuikChange SDM Kit, Stratagene),
which deleted the amino acids alanine 146 and arginine
147 with the following deletion primers: 5′-GGTCAA-
TAATGTCCCAATGCAGTATGAAAAAATAACGGCTC-3′
and 5′-GAGCCGTTATTTTTTCATACTGCATTGGGA-
CATTATTGACC-3′. The properties of this mutant were
examined in detail previously.4,5 The truncated mutants
D123 (PLY containing domains 1, 2 and 3) and D4 (PLY
containing domain 4) were purified in the same way. A
detailed analysis of the lytic capacity of the GFP-tagged
toxin confirmed that it behaved similarly to wild-type PLY
(Supplementary Fig. S3).
Cell culture
Primary astrocytes were prepared from the cortices of
newborn C57BL/6 mice (postnatal day 3) asmixed cultures
withmicroglia in Dulbecco'smodified Eagle's medium (high
glutamate) (Gibco, Invitrogen GmbH, Karlsruhe, Germany)
supplemented with 10% foetal calf serum (PAN Biotech
GmbH, Aidenbach, Germany) and 1% penicillin/strepto-
mycin (Gibco). Fourteen days after being seeded in 75-cm2
cell culture flasks (Sarstedt AG & Co. KG, Nuembrecht,
Germany), the cells were reseeded onto chamber slides
(BD Falcon, Franklin Lakes, NJ, USA), chambered cover-
glass bottom slides (Nunc/Thermo Scientific, Rockford, IL,
USA) or dishes (Sarstedt) coated with poly-L-ornithine
(Sigma-Aldrich Corp., St. Louis, MO, USA).
Labelling of PLY with Atto488
Atto488, in the form of an NHS ester (Atto-Tec GmbH,
Siegen, Germany), was added to PLY in a 4-fold molar
excess [in 0.1 M N,N-bis(2-hydroxyethyl)glycine buffer,
pH 9]. Alkaline conditions were maintained during the
labelling reaction, which was performed for 30 min at room
temperature (RT) in the dark. The excess dye was
removed using a gel-filtration column (10 DG, BioRad,
Germany). Covalent bonding was verified via SDS-PAGE
analysis of the eluted fractions on a UV transilluminator
(FluoChemQ, Alpha Innotech, Santa Clara, CA, USA). A
detailed analysis of the lytic capacity of the labelled toxinconfirmed that it behaved similarly to wild-type PLY
(Supplementary Fig. S2).
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde (Carl Roth,
Karlsruhe, Germany) in phosphate-buffered saline (PBS)
(pH 7.3) for 30 min, permeabilised with 0.1% Triton X-100
(Carl Roth) and blocked with 4% bovine serum albumin
(Carl Roth). Actin staining was performed using phalloidin-
Alexa555 (1:200) (Invitrogen).
FRET detection in fixed cells via acceptor
photobleaching
Primary mouse astrocytes were challenged with a sub-
lytic concentration of PLY-Atto488, fixed and then stained
with phalloidin-Alexa555 after permeabilisation on ice with
0.1% Triton X-100 for 3 min. The analysis was performed
on a Leica LSM SP5 confocal microscope (Leica Micro-
systems, Mannheim, Germany) with 488 nm excitation of
Atto488 and 561 nm excitation of Alexa555. The bleaching
was performed with maximum laser power at 561 nm, and
the images were analysed with the ImageJ software
package (version 1.47a; National Institutes of Health,
Bethesda, MD, USA).
Preparation of G-actin and F-actin
To obtain G-actin, we reconstituted non-muscle actin
(Cytoskeleton, Denver, USA) isolated from human plate-
lets (N99% pure) in 5 mM Tris–HCl, pH 8.0, 0.2 mM
CaCl2, 0.2 mM ATP, 5% (w/v) sucrose, and 1% (w/v)
buffer (Cytoskeleton). Monomeric actin was polymerised in
1:10 diluted APB (500 mM KCl, 20 mMMgCl2, and 10 mM
ATP) (Cytoskeleton), followed by incubation of the solution
at 24 °C for 1 h. Preformed F-actin was reconstituted in
general actin buffer (5 mM Tris–HCl, pH 8.0, and 0.2 mM
CaCl2) (Cytoskeleton).
FRAP experiments
Non-muscle G-actin purified from human platelets con-
taining covalently linked rhodamine at randomsurface lysine
residues (Cytoskeleton) was used for the imaging of actin
polymerisation. Actin-rhodamine was reconstituted in gen-
eral actin buffer (see above) to a final concentration of
250 μg/ml. To achieve the polymerisation of actin, we added
APB (Cytoskeleton). PLY was also used at a concentration
of 250 μg/ml (actin/PLY ratio of 1:0.8) and allowed to
polymerise at 37 °C for 1 h. Subsequently, 5 μl of the
suspension was applied to a glass slide with a coverslip.
Imaging was performed on a Leica LSM SP5 confocal
microscope (Leica Microsystems). Bleaching was per-
formed at 561 nm with maximum laser power and followed
by scanning at 561 nm with a laser power of 10%. The
analysis was performed with the ImageJ software package.
Actin-binding spin-down assays
Freshly prepared F-actin (see above) was incubated
with PLY or its mutant variants and fragments. The actin
645Actin–Cytolysin Pneumolysin Interaction(4.6 μM) was incubated with the PLY variants (2.5 μM) for
1 h at 24 °C in a total volume of 100 μl, which was followed
by centrifugation at 150,000g. The pellet containing actin
was resuspended in 50 μl of MilliQ water. SDS sample
buffer (containing β-mercaptoethanol, see above) was
added to both fractions, and the samples were boiled and
subsequently analysed by SDS-PAGE.ELISAs for the detection of protein interactions
F96 Cert. Maxisorp Immuno plates (Nunc/Thermo
Scientific, Waltham, MA, USA) were coated overnight
with PLY at concentrations between 5 and 300 μg/ml (in
the stoichiometric ELISA experiments) or with 20 μg/ml of
the PLY variants (in the domain interaction identification
tests). The amount of adsorbed protein was evaluated and
compared among different PLY forms/fragments by the
copper iodide staining protocol for microtiter plates,30 and
the actin absorption results were normalised to the
adsorbed protein amount, as the coating differences
never exceeded 20%. Nonspecific binding sites were
blocked with 10% foetal calf serum (PAN Biotech GmbH)
for 1 h. G-actin was added at a concentration of 20 μg/ml.
After a 2-h incubation at RT, the wells were washed three
times with 0.05% 1× PBS-T (for PBS components, see
above; Tween-20, Carl Roth). Then, an anti-actin antibody
(1:1000; Cytoskeleton) was added, and the samples were
incubated for 1 h at RT. Finally, a horseradish-peroxidase-
conjugated goat anti-rabbit antibody (Jackson) was
applied for 30 min, and the reaction was visualised using
TMB (Nalgene/Thermo Scientific, Waltham, MA, USA).GUV experiments
GUVs were produced as described previously.31 Briefly,
a mixture of 25% 1,2-Dioleoyl-sn-glycero-3-phosphocho-
line, 35% 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
and 40% cholesterol (all from Sigma) in chloroform was
employed for the electroformation of GUVs with a Vesicle
Prep Pro device (Nanion Technologies GmbH, Munich,
Germany) according to the manufacturer's instructions.
GUVs were loaded internally with GFP-tagged PLY
variants via cold fusion between the GUVs and protein
liposomes at 4 °C.16 The efficiency of the fusion was
verified using protein liposomes containing fluorescent
secondary antibodies. The protein liposomes were pre-
pared with the film hydration method using 40%DOPC and
60% DPPC, as described previously.32 Free, non-encap-
sulated PLY was captured via incubation for 2 h on a
shaker platform with a cholesterol-containing trap that
consisted of a dried multilamellar film composed of a
cholesterol-containing lipid mixture, such as the mixture
used to form the GUVs. The liposome mixture was tested
for cytotoxicity and toxin binding, and it demonstrated a
complete lack of free PLY. The fused GUVs demonstrated
proper PLY-GFP staining localised on their surface. To
verify the orientation of PLY-GFP on the surface of the
GUVs, we performed a trypan blue assay (see Supple-
mentary Fig. S3). For the actin polymerisation experi-
ments, GUVs with or without PLY were incubated with
rhodamine-labelled G-actin in a final mixture containing
7.5 μM G-actin, 160 nM Arp2/3 (Cytoskeleton) complex
and 1 mM ATP APB32 (see Fig. 4a for a diagram).Statistical analysis
Statistical analysis was performed usingGraphPad Prism
4.02 for Windows (GraphPad Software Inc., La Jolla, CA,
USA). The statistical tests included a Mann–Whitney U test
(comparing two groups differing in one parameter) and a
one-way ANOVA with a Bonferroni post test (comparing
three or more groups differing in one parameter).
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jmb.2012.11.034
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